ARTHUR-D.-LITTLE
11.1.2021 15:33:34 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced that it has been awarded multiple high impact projects by the European Space Agency (ESA) to help identify the most promising services for next generation satellite communication (SatCom) infrastructure. ADL will conduct a major consultation process with key members of the transport, energy, infrastructure and media industries, plus stakeholders in law enforcement and emergency services, to identify and assess potential applications and services that could be delivered via satellite in the next decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005719/en/
ADL will be responsible for four studies in total. Three of the studies are part of the Advanced Research in Telecommunications Systems (ARTES) 4.0 Strategic Programme Line “Space Systems for Safety and Security” (4S), and are supported by the Italian Space Agency:
- Safety of Future Transport
- Safeguarding Essential Services
- Satellite Applications for Public Safety
As part of its ‘Open Consulting’ approach, ADL will conduct these studies with input from Distretto Tecnologico Aerospaziale (DTA).
The fourth study is an ARTES4.0 Business Applications Feasibility Study and is supported by the Norwegian Space Agency:
- Port of the Future
ADL will conduct this study in collaboration with Marlink and CLS.
With society and the economy dependent on telecommunications networks, the aim of 4S is to support the development of secure SatCom systems to both improve digital infrastructure resilience across Europe and the rest of the world, and provide innovative services and solutions. As terrestrial networks become increasingly vulnerable to disruption and attack, integrating next generation SatCom systems with the existing digital infrastructure can help make these networks more resilient and secure.
The Safety of Future Transport study will focus on how next generation SatCom solutions can increase safety and efficiency in the fast-evolving aviation, maritime and railway sectors, with potential applications relating to unmanned aircraft and ships, and automated traffic management systems. Safeguarding Essential Services will focus on how SatCom can help protect critical infrastructure such as energy utilities as well as public media. Satellite Applications for Public Safety will focus on how SatCom can supplement and support existing Public Protection and Disaster Relief (PPDR) networks used by first responders such as the police, fire brigade, health services and search & rescue.
The Port of the Future study will assess the technical feasibility and economic viability of new Earth observation and SatCom-based services for the port industry, focusing not only on operations of the port itself, but also on monitoring their environmental impact in terms of air and water quality.
Francesco Marsella, Managing Partner and Global S&O Practice Leader at ADL , comments: "SatCom has an increasingly vital role to play in protecting our society and making its infrastructure more secure and resilient. As terrestrial networks become more prone to failure, whether due to natural disaster or cyberattack, SatComs can support and maintain European telecoms systems. These studies will be key to developing existing satellite systems and identifying the services of the future.”
Lars Thurmann-Moe, Managing Partner, ADL Norway , comments: “It is not always appreciated quite how important the maritime sector remains, with the great majority of goods still transported by sea. SatCom is already central to modern maritime operations in terms of communication and navigation, but there is still so much more that can be done to improve these operations, and also reduce the industry’s environmental footprint – for instance, helping to quickly pinpoint oil spillages.”
Matteo Ainardi, Head of the Aerospace & Defense Competence Center at ADL , comments: "The satellite industry is today being disrupted by the introduction of new technologies such as large scale low earth orbit (LEO) constellations, reusable launchers and phased-array antennas. It is the right time to assess the evolving demand for SatCom solutions, and develop a next generation SatCom capability that can leverage these major technological breakthroughs to the benefit of the European society and economy. ADL is highly involved in the commercial space sector – as such, we are very pleased to be working with ESA on these studies, and look forward to applying our industry expertise to help define the SatCom-based services and applications of the future.”
To find out more about Arthur D. Little’s work in the space industry, please visit www.adlittle.com/en/industries/aerospace-defense
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005719/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom